Less than 1% of injected chemotherapy reaches the tumor. The rest disperses throughout the body — causing severe side effects and wasting billions annually in systemic drug loss (Wilhelm et al., ACS Nano 2016). This inefficiency stems from a fundamental limitation of most chemotherapies: they lack spatial precision, indiscriminately affecting both healthy and cancerous tissue. As a result, therapeutic potency is restricted, treatment efficacy fluctuates, and patient outcomes remain suboptimal.
The Solution: Envoy-Carrier-Drug-Conjugates (ECDC’s)
We aim to overcome these critical limitations by enabling direct, externally guided delivery and localized release of potent therapeutics — representing a new precision paradigm for solid tumor treatment. At Envoy Chemical Technologies, we’re offering solutions through our:
o Envoy NP Carriers: Drugs are covalently attached to our carrier platform. o Magnetically guided platform: Our Envoy carrier-conjugates are steered to tumor sites using external magnetic fields — concentrating the carriers before any drug is released. o RF-triggered activation: Payloads are released only at and near the tumor under a remote radiofrequency (RF) field, enabled by our novel linker chemistry.
Current Development Stage
As we initiate proof-of-concept phase of the Envoy(I) prototype, we’d like to share a first look at the core technological research objectives driving our development. The ECDC-platform currently resides at TRL 3, which we hope to accelerate in the near future. Objectives include: o Synthesis & Characterization Gidealain Probes o Standardization & Characterization Envoy Carriers o Conjugation and Evaluation of RF-cleavable linker technology o Validation of Release Performance in Physiological conditions
Funding Needs
There is still a long road ahead to make this technology a reality. We are therefore actively looking for funding opportunities to accelerate the R&D. We’re currently raising €250k - €2 million to: o Cover equipment and reagent costs o Cover lab-space rent & measurement equipment o Run preliminary in vitro & in vivo experiments o Secure IP, patents and cover other legalities o Remuneration and hiring o Cover additional expenses
